← Back to Search

Peptide

FAP-2286 PET Imaging for Fibrosis

Phase 1
Recruiting
Led By Thomas A Hope, MD
Research Sponsored by Thomas Hope
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 31 days
Awards & highlights

Study Summary

This trial will help researchers learn if FAP-2286 can be used to help identify different types of fibrosis and if it is safe for human use.

Who is the study for?
This trial is for adults with confirmed pathologic fibrosis affecting the liver, lungs, or heart. Participants must understand and sign a consent form. It's not suitable for pregnant individuals or those unlikely to follow the trial procedures.Check my eligibility
What is being tested?
The study tests a new imaging agent called 68Ga-FAP-2286 using PET scans to detect fibrosis in the liver, lungs, and heart. The agent binds to proteins that are more common in these types of fibrosis.See study design
What are the potential side effects?
Since this is an imaging study primarily involving PET scans and a novel tracer (68Ga-FAP-2286), side effects may include reactions at the injection site or allergic responses but will be detailed as data becomes available.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 31 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 31 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Median peak standardized uptake value (SUV) in myocardium region
Liver
Lung
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort 3: Myocardial FibrosisExperimental Treatment2 Interventions
Patients with myocardial fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
Group II: Cohort 2: Pulmonary FibrosisExperimental Treatment2 Interventions
Patients with pulmonary fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
Group III: Cohort 1: Liver FibrosisExperimental Treatment2 Interventions
Patients with liver fibrosis will receive a single administration of 68Ga-FAP-2286 prior to PET imaging.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography (PET)
2018
Completed Phase 4
~1390

Find a Location

Who is running the clinical trial?

Thomas HopeLead Sponsor
9 Previous Clinical Trials
1,578 Total Patients Enrolled
Clovis Oncology, Inc.Industry Sponsor
64 Previous Clinical Trials
11,641 Total Patients Enrolled
Thomas A Hope, MDPrincipal InvestigatorUniversity of California, San Francisco
3 Previous Clinical Trials
497 Total Patients Enrolled

Media Library

68Ga-FAP-2286 (Peptide) Clinical Trial Eligibility Overview. Trial Name: NCT05180162 — Phase 1
Pulmonary Fibrosis Research Study Groups: Cohort 1: Liver Fibrosis, Cohort 3: Myocardial Fibrosis, Cohort 2: Pulmonary Fibrosis
Pulmonary Fibrosis Clinical Trial 2023: 68Ga-FAP-2286 Highlights & Side Effects. Trial Name: NCT05180162 — Phase 1
68Ga-FAP-2286 (Peptide) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05180162 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is 68Ga-FAP-2286 a safe medication for human beings?

"68Ga-FAP-2286 has only been evaluated in a Phase 1 clinical trial, so there is limited data to support its safety."

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
University of California, San Francisco
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
2
Recent research and studies
clinicaltrials.govStudy
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
Thomas Hope 2021. "Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05180162.
All > Liver Cirrhosis > Pulmonary Fibrosis
~7 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top